Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease
Executive Summary
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
You may also be interested in...
Rigel’s Tavalisse Hits Pothole In Label Expansion For Hemolytic Anemia
Tavalisse misses the primary endpoint in a 90-patient Phase III trial in warm autoimmune hemolytic anemia, but Rigel contends a high placebo response in Eastern Europe confounded the results.
Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Keeping Track: A Fresh Wave Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.